Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance

Gilead Sciences, Inc.Trade
Invesco WilderHill Clean Energy ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Invesco WilderHill Clean Energy ETF — how do they compare? Gilead Sciences, Inc. trades at $135.46 (market cap $164.99B), while Invesco WilderHill Clean Energy ETF trades at $34.96. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Invesco WilderHill Clean Energy ETF pays none. Which is the better fit depends on your goals.

GILDPBW
Market Cap
$164.99B
Sector
HealthSector/Thematic
52-Week High
$155.80$46.99
52-Week Low
$110.56$23.73
Enterprise Value
$188.06B
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Invesco WilderHill Clean Energy ETF

PBW trades at $34.81, up 3.48% today, with a neutral technical signal and mixed moving averages. The clean energy ETF shows strength amid sector tailwinds from geopolitical tensions and data center demand, though it faces volatility from interest rate sensitivity. A dividend of $0.24 is scheduled for June 2026, but key valuation ratios like P/E and P/S are unavailable in the data.

The outlook hinges on clean energy adoption trends and Federal Reserve policy, with opportunities in global investment shifts but risks from rate cycles and oil price swings. Analyst sentiment is divided, reflecting the ETF's exposure to macroeconomic factors over company-specific fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Invesco WilderHill Clean Energy ETF

PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.

Read more on PBW